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List of Abbreviations 
3beta-HSD  hydroxysteroid dehydrogenase/isomerase  
γ-GCS  Gamma-glutamyl cysteine synthetase 
COX-2  cyclooxygenase-2  
DR   diabetic retinopathy  
GPx   glutathione peroxidase 
GSH  reduced glutathione 
IBD  inflammatory bowel disease 
ICAM-1 intercellular adhesion molecule-1 
IFN(gamma) interferon-gamma  
IL-1β   interleukin-1beta  
IL-8   interleukin-8  
LPS   lipopolysaccharide  
MCP-1  monocyte chemoattractant protein-1 
MPO   myeloperoxidase 
SHBG   sex hormone-binding globuline  
SOD  superoxide dismutase 
THIF  5,7,3’,4’-tetrahydroxyisoflavone. 





Genistein is abundant in soya and related products and its consumption is associated with 
numerous health benefits, including oestrogenic activity, anticancer effects, antioxidant 
actions and anti-inflammatory activity. However, whilst at high concentration in soy, the 
biological effects of genistein, in cells and tissues, will be dependent on its absorption, 
metabolism and distribution. In foods, isoflavones are predominantly present as glycosylated 
forms, i.e. genistin.  However these are hydrolyzed prior to absorption, releasing the aglycone, 
i.e. genistein, which may be absorbed and may undergo further biotransformation, including 
intracellular metabolism.  In the case of genistein this intracellular metabolism may lead to the 
formation of bioactive metabolites such as 5,7,3’,4’-tetrahydroxyisoflavone (THIF), which itself 
will undergo conjugation with cellular thiols such as glutathione (GSH) to yield glutathionyl 
conjugates of THIF. Studies have suggested that THIF and its derivatives may be partly 
responsible for the biological effects of genistein in vivo.  Indeed, it may act influence the 
proliferation of cancer cells through its effects of DNA oxidation and the activation of 




1. Genistein and its biological activities 
The isoflavone genistein (5,7,4’-trihydroxyisoflavone) (Figure 1) is present primarily in 
soybeans and a variety of legumes (Reinli and Block 1996), where its content can differ 
depending on the variety of soybean, the year harvested, geographic location and plant part 
(Delmonte and Rader 2006). Non-soy legumes such as lentils and other types of beans do 
not contain appreciable amounts of genistein (Liggins et al 2000). However, genistein can also 
occur in soy products in the form of its glycoside (Figure 1) genistin (Liggins et al 2000; Reinli 
and Block 1996). Genistein exhibits a wide range of biological effects that contribute to its 
potential health benefits (Head 1998), such as oestrogenic activity (Cassidy et al 1994), 
anticancer effects (Messina and Bennink 1998), antioxidant actions (Cai and Wei 1996), and 
anti-inflammatory activity (Fanti et al 2006). 
1.1. Oestrogenic activity 
Isoflavones are structurally similar to oestrogens (Miksicek 1995) and can function both as 
oestrogen agonists and antagonists depending on the hormonal milieu and the target tissue 
and species under investigation (Molteni et al 1995). Genistein’s anti-oestrogenic effects are 
due to its ability to bind to the oestrogen receptor (Wang et al 1996; Yearley et al 2007), 
therefore suppressing the more harmful effects of oestrogens, such as their effects on 
oestrogen-sensitive cancers (Anthony et al 1998; Goodman et al 1997; Horn-Ross et al 2003).  
For example, in MCF-7 breast cancer cells, which are known to be estrogen receptor positive, 
genistein is able to stimulate estrogen-responsive pS2 mRNA expression and compete with 
[3H]-estradiol binding to the estrogen receptor with 50% inhibition (Wang et al 1996). 
Furthermore, isoflavones have been found to exert an estrogenic effect in both the absence 
or presence of endogenous estrogen (Adlercreutz and Mazur 1997).  Alternatively, genistein 
may reduce oestrogenic activity via its ability to induce the production of sex hormone-binding 
globuline SHBG, thus leading to a faster clearance of sex hormones (including oestrogens) 
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(Mousavi and Adlercreutz 1993) and a reduced risk of hormone-sensitive breast and prostate 
cancer (Messina and Hilakivi-Clarke 2009; Smith et al 2008).  Similarly, genistein is known to 
inhibit many of the enzymes involved in the biosynthesis and metabolism of steroid hormones 
(Head 1998). For example, genistein has direct effects on cellular progesterone synthesis 
which involve the inhibition of hydroxysteroid dehydrogenase/isomerase (3beta-HSD) enzyme 
activity across the post-cyclic AMP pathway. It directly affects cellular progesterone synthesis 
through its inhibition of 3beta-HSD gene expression and down-regulation of its transcription 
(Tiemann et al 2007).  
There is convincing evidence that a diet rich in soy-protein, which contains genistein, has an 
impact on the hormonal status and the regulation of the menstrual cycle of premenopausal 
women (Cassidy et al 1994). A daily intake of 60g of soy protein (containing 45 mg isoflavones) 
for 1 month significantly increased follicular phase length and/or delayed menstruation, 
significantly suppressed the mid-cycle surges of luteinizing hormone and follicle-stimulating 
hormone and increased plasma estradiol concentrations in the follicular phase (Cassidy et al 
1994).  These effects were potentially associated with lower risk of breast cancer (Cassidy et 
al 1994; Henderson et al 1985). 
 
1.2. Anticancer effects 
Interest in genistein as a anticancer agent arose due to population-based data indicating a link 
between genistein consumption and a decreased risk of mortality from several types of cancer, 
in particular prostate and breast cancer (Pavese et al 2010).  Epidemiological studies indicate 
a protective effect of isoflavone ingestion against breast cancer in premenopausal women and 
women who had high soy intakes during adolescence (Peeters et al 2003; Piller et al 2006), 
whereas in postmenopausal women the data vary depending on the study (Jones et al 2002; 
Ju et al 2006; Ju et al 2002).  Genistein is a potent inhibitor of the growth of breast cancer 
cells, whereas its beta-glucoside genistin has little effect (Peterson and Barnes 1991, 1993). 
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The effects of genistein on breast cancer cell growth and proliferation were studied in 
estrogen-receptor negative (MDA-468) and positive (MCF-7 and MCF-7-D-40) cell lines and 
it was ascertained that the presence of the estrogen receptor is not required for genistein to 
inhibit the cancer cell growth (Peterson and Barnes 1991). The estrogen-independent effects 
of genistein can be due to their ability, or the ability of one of their metabolites, to block cell 
cycle progression through direct effects on intracellular signalling (Nguyen et al 2006).  For 
example, genestein has been shown to be capable of causing a cell cycle block in the G2/M 
phase in vitro (Cappelletti et al 2000; Santell et al 2000) and an overexpression of cyclin 
dependent kinase inhibitor p21WAF1 in breast cancer cells, leading to cell cycle arrest (Chinni 
et al 2003).  Other mechanisms whereby genistein can exert its anticancer properties include 
induction of apoptosis (Sergeev 2004; Xu and Loo 2001), inhibition of tyrosine kinases 
(Mitropoulou et al 2002; Morton et al 1999), modulation of the MAPK kinase signalling (Li et 
al 2006) alterations in the phosphatidylinositol 3-kinase cascade (Lee et al 2001) and inhibition 
of DNA topoisomerases (McCabe and Orrenius 1993).  
The relationship between isoflavone supplementation and prostate cancer has also been 
extensively investigated. Male rats fed with genistein (0, 25 and 250 mg /kg) over their lifetime 
led to an inhibition of the development of N-methylnitrosourea-induced prostate invasive 
adenocarcinomas, in a dose-dependent manner (Wang et al 2002).  It has been proposed that 
the regulation of AR/Akt/PTEN pathway by genistein may be one of the molecular mechanisms 
by which it inhibits proliferation and induces apoptosis in prostate cancer cells (Wang et al 
2009).  The Akt-GSK-3 pathway and its downstream effectors have also been identified as 
targets for the chemopreventive action of genistein in transgenic adenocarcinoma mouse 
prostate model (TRAMP/FVB) mice, where incorporation of genistein in the diet significantly 
inhibited the activation of Akt, restored the activation of GSK-3beta, reduced cyclin D1 levels 
post-transcriptionally and maintained the expression of the cadherin-1 complex via down-
regulation of snail-1, decreasing the proliferative potential, retarding cancer progression and 
maintaining the integrity of the prostatic epithelial cells in vivo (El Touny and Banerjee 2007). 
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Another mechanism of increased prostate cancer cell death by genistein is proposed to occur 
via its ability to inhibit NF-kappaB signalling, leading to altered expression of regulatory cell 
cycle proteins such as cyclin B and/or p21WAF1/Cip1, thus promoting G2/M arrest. These 
findings support the important and novel strategy of combining genistein with radiation for the 
treatment of prostate cancer (Raffoul et al 2006). 
 
1.3. Antioxidant action 
Genistein, similar to other isoflavones, possesses a relatively strong antioxidant potential in 
vitro (Han et al 2009), and exerts its antioxidant actions by scavenging free radicals (Kim et al 
), chelating metals (Dowling et al ), inhibiting the production of oxidizing species such as H2O2 
(Sethy-Coraci et al 2005), and by enhancing the activity of endogenous antioxidant enzymatic 
systems, such as catalase (Cai and Wei 1996).  Whilst direct antioxidant actions in vivo are 
highly unlikely (Williams et al 2004), at physiologically achievable concentrations of 5 nM 
genistein increased intracellular-reduced glutathione (GSH) levels by approximately 10 %, 
whereas cellular alpha-tocopherol and uric acid remained unchanged (Guo et al 2002).  The 
mechanisms behind increases in GSH may include the effect of isoflavones on enzymes 
involved in the synthesis of GSH such as γ-GCS (Guo et al 2002). Dietary administration of 
genistein for 30 days in mice increases the activity of antioxidant enzymes such as catalase, 
superoxide dismutase, glutathione peroxidase and glutathione in various organs, including 
skin, small intestine, liver, kidney, and lung(Cai and Wei 1996). Furthermore , treatment of 
macrophages with genistein reduces LPS induced GSH depletion and induces superoxide 
dismutase (SOD) and catalase (Choi et al 2003).  Similar effects have been reported in rats, 
where feeding the animals with an isoflavone-rich diet increased glutathione peroxidase and 
glutathione reductase activities, blood glutathione levels and glutathione S-transferase levels 
in kidney (Appelt and Reicks 1999).  
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1.4. Anti-inflammatory activity 
Genistein has been shown to have an effect on the production of inflammatory mediators in 
human peripheral blood mononuclear and polymorphonuclear leukocytes stimulated with 
lipopolysaccharide (LPS) and interferon-gamma (IFN(gamma) (Richard et al 2005). 
Genistein’s anti-inflammatory activity has also been noted in human brain microvascular 
endothelial cells, where it dose-dependently inhibited cytokine-induced up-regulation of pro-
inflammatory mediators such as tumour necrosis factor-alpha (TNF-α), interleukin-1beta (IL-
1β), monocyte chemoattractant protein-1 (MCP-1), interleukin-8 (IL-8), and intercellular 
adhesion molecule-1 (ICAM-1)  and cytokine-induced transmigration of blood leukocytes (Lee 
and Lee 2008).  Exposure to high amounts of genistein, as occurs in traditional East Asian 
diets, where the mean total intake of isoflavones is estimated between 17 and 47 mg/day 
(Vergne et al 2009), may be associated with a lower incidence of inflammatory bowel disease 
(IBD) (Loftus 2004).  Indeed, the risk of IBD appears to increase in Asian immigrants adopting 
western lifestyles, suggesting a protective role for isoflavones (Loftus 2004). To confirm this 
hypothesis, the effect of orally administered genistein on the inflammatory response to 2,4,6-
trinitrobenzenesulfonic acid-induced chronic colitis in rats has been investigated and indicates 
that genistein exerts beneficial anti-inflammatory effects by inhibiting molecular and 
biochemical inflammatory markers in the colon, specifically cyclooxygenase-2 (COX-2) and 
myeloperoxidase (MPO) (Seibel et al 2009). Diabetic retinopathy (DR) is also associated with 
microglial activation and increased levels of inflammatory cytokines and the efficacy of 
genistein for alleviation of diabetes-induced retinal inflammation has been studied in an animal 
model of diabetes. Genistein was found to be effective in dampening diabetes-induced retinal 
inflammation by reducing TNF-α release and inhibiting ERK and P38 phosphorylation in 
activated microglial cells (Ibrahim et al 2010).  
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2. Intracellular formation of the genistein metabolite 5,7,3’,4’-
tetrahydroxyisoflavone (THIF) 
The biological effects of genistein are undoubtedly affected be its metabolism by phase II 
metabolic conjugation to glucuronic acid or sulphuric acid, catalyzed by UDP-glucuronyl 
transferase or sulfotransferase enzymes in the intestinal epithelium and in the liver. In addition, 
intracellular metabolism of genistein may also act to affect it cellular actions.   Genistein 
undergoes further transformation intracellularly to yield novel bioactive metabolites.  For 
example, in tumorigenic breast epithelial cells, genistein is selectively taken up into the cell 
and is subjected to significant intracellular metabolism by CYP450 enzymes leading to the 
formation of both 5,7,3’,4’-tetrahydroxyisoflavone (THIF; orobol) and two glutathionyl 
conjugates of THIF (Nguyen et al 2006). A scheme of the described metabolic pathways is 
presented in figure 2. It iss also shown that the co-treatment with cimetidine prevents the 
conversion of genistein to THIF, and because cimetidine is known to inhibit the CYP450 
isoforms 1A2, 2C9, 2C19, 2D6, and 3A4, it is likely that one of these isoenzymes is responsible 
for the conversion of genistein to THIF in T47D cells (Nguyen et al 2006). Previously, it has 
been suggested that isoflavone metabolism in transformed but not non-transformed breast 
epithelial cells may modulate the growth inhibitory effects of genistein (Peterson et al 1996). 
Glutathionyl conjugates of THIF in cells may be formed either enzymatically via the action of 
glutathione S-transferase or non-enzymatically via oxidative metabolism of THIF and 
subsequent reaction of THIF o-quinone with the cellular thiol GSH. However, the inhibition of 
glutathione S-transferase does not block glutathione conjugate formation, indicating that the 
latter is more likely to occur (Nguyen et al 2006). Conjugations with thiols, such as glutathione, 
represent a major target for quinones, and the detoxification of quinones by GSH conjugation 
is generally considered to be cytoprotective (Monks and Lau 1997). Glutathionyl conjugates 
from a variety of polyphenol quinones have been observed in cellular systems and display a 
wide array of biological activities (Corona et al 2006; Monks and Lau 1997; Spencer et al 
2003). Indeed, the redox activity of polyphenols is frequently enhanced following conjugation 
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with GSH (Monks and Lau 1997) and as GSH conjugation is often coupled to the subsequent 
export of the adduct from cells, the conjugation of THIF appears to represent a detoxification 
pathway (Monks and Lau 1997; Spencer et al 2003). 
 
3. 5,7,3’,4’-tetrahydroxyisoflavone (THIF) and cancer 
The exposure of breast epithelial cells to physiological concentrations of genistein selectively 
induces growth arrest and G2-M phase cell cycle block in tumorigenic (T47D) but not non-
tumorigenic (MCF10A) breast epithelial cells (Nguyen et al 2006).  These effects of cancer 
cell proliferation were paralleled by significant differences in the association of genistein with 
cells and in particular its intracellular metabolism (Nguyen et al 2006). Previously, it had been 
suggested that isoflavone metabolism in transformed but not non-transformed breast epithelial 
cells may modulate the growth inhibitory effects of genistein (Peterson et al 1996). In 
agreement with this hypothesis, genistein appeared to be selectively taken up into tumorigenic 
breast epithelial cells and subjected to significant intracellular metabolism leading to the 
formation of THIF and two glutathionyl conjugates of THIF (Nguyen et al 2006).  In contrast, 
there was minimal cell-association of genistein with MCF10A cells and no subsequent 
formation of free THIF (Nguyen et al 2006). In breast cancer cells THIF formation triggers the 
activation of the MAP kinase p38 (Figure 3). Active p38 prevents the phosphorylation of cyclin 
B1 and hence its transport to the nucleus, an event essential for correct functioning of the 
cdc2-cyclin B1 complex.  In addition, active p38 may undergo translocation to the nucleus 
where it directly inhibits the phosphorylation/activation of cdc2, thereby blocking entry of cells 
into mitosis (G2-M block) (Nguyen et al 2006). These data suggest that the formation of THIF 
is crucial in driving the anti-cancer effects of genistein in vivo, in particular by inhibiting the 
proliferation of cancer cells but not affecting normal cell function.  Further evidence relating to 
the cellular actions of the genistein metabolite, THIF, were elucidated in human breast 
carcinoma cells and summarized in figure 3 (Vauzour et al 2007).  Here THIF induced a G2-
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M cell cycle arrest in T47D tumorigenic breast epithelial cells which was mediated by the 
activation of ataxia telangiectasia and Rad3-related kinase (ATR) via its phosphorylation at 
Ser428 (Vauzour et al 2007).  This activation of ATR appeared to result from THIF-induced 
increases in intracellular oxidative stress, a depletion of cellular GSH and an increase in DNA 
strand breakage (Vauzour et al 2007).  These events led to the downstream inhibition of cdc2, 
which was accompanied by the phosphorylation of both p53 (Ser15) and Chk1 (Ser296) and the 
de-activation of cdc25C phosphatase.  It was suggested by the authors that the anti-
proliferative actions of THIF may be mediated by initial oxidative DNA damage, activation of 
ATR and downstream regulation of the p53 and Chk1 pathways leading to cell cycle arrest in 
G2-M (Vauzour et al 2007). These data sets suggest that the formation of THIF may mediate 
the effects of genistein on cancer cells.  This hypothesis is in agreement with other 
investigations, which reported the effects of THIF (orobol) and other isoflavones (genistein, 
daidzein and 7,8,4'-trihydroxyisoflavone) on angiogenesis and endothelial cell proliferation 
(Kiriakidis et al 2005).  In a chicken chorioallantoic membrane assay; all compounds had the 
capacity to inhibit angiogenesis, albeit with different potencies (genistein > THIF > daidzein 
(48.98 %) and 7,8,4'-TriOH (24.42 %), and also inhibited endothelial cell proliferation, with 
THIF causing the greatest inhibition at lower concentrations (Kiriakidis et al 2005). 
 
4. 5,7,3’,4’-tetrahydroxyisoflavone (THIF) and endothelial function 
Genistein has been shown to be able to protect endothelial cells against damage induced by 
oxidative stress and decreases intracellular glutathione levels (Hernandez-Montes et al 2006).  
These effects appear to also be mediated by genistein intracellular metabolism. When 
genistein enters cells it is subject the CYP450-induced intracellular metabolism yielding THIF.  
THIF may also react with intracellular GSH to form the adduct THIF-GSH (figure 3), inducing 
a reduction of intracellular GSH and an increased DNA damage (Hernandez-Montes et al 
2006). Genistein and THIF are also able to induce the transcription of antioxidant enzymes: 
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more specifically genistein directly activate the translocation of Nrf2, which will increase the 
transcription of γ-GCS, leading to increases in GSH synthesis, whereas THIF stimulates the 
release of Nrf1 with the subsequent translocation into the nucleus where it may interact with 
the electrophile response element and induce the transcription of GPx (Hernandez-Montes et 
al 2006). The intracellular formation of glutathionyl conjugates of THIF may result either from 
the action of glutathione-S-transferase or from the autoxidation of THIF and subsequent 
reaction of THIF o-quinine with GSH (Hernandez-Montes et al 2006).  These finding are in 
agreement with other studies that indicate that glutathionyl conjugates from a variety of 
polyphenol quinones have been observed in cellular systems and display a wide array of 
biological activities (Corona et al 2006; Monks and Lau 1997; Spencer et al 2003).  It appeared 
that the protective effects observed in endothelial cells in response to genistein exposure were 
dependent on the induction of the enzyme glutathione peroxidise (GPx), due to increases in 
both GPx mRNA and enzyme activity.  It was suggested that genistein and its intracellular 
metabolites protective effects on endothelial cells were depend primarily on the activation of 
glutathione peroxidase mediated by Nrf1 activation, and not on Nrf2 activation or increases in 
glutathione synthesis (Hernandez-Montes et al 2006). 
 
5. Summary 
The cellular mechanism of action of genistein will be dependent on the cellular metabolism 
and uptake of the compound. Genistein enters the cells where it is hydroxylated to form 
5,7,3’,4’-tetrahydroxyisoflavone (THIF). It is suggested that THIF formation is crucial for its 
cellular activity and can be mediated by interactions of the newly formed cellular metabolite 
with signalling pathways. THIF is generated by the action of CYP450 enzymes in cells 
(Nguyen et al 2006) and the catechol group-containing metabolite is observed to persist within 
the cells for up to 24 h without undergoing O-methylation (Vauzour et al 2007) as has been 
observed for other catechol containing polyphenols (Corona et al 2006; Spencer et al 2003) . 
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Indeed cellular actions of isoflavones are cell-type specific and also depend on its P450-
related metabolism, oxidative metabolism, and GSH-conjugation (Hernandez-Montes et al 
2006). Experiments conducted by testing both genistein and daizein in endothelial cells 
showed that only genistein significantly protected against the oxidative injury induced by 
hydrogen peroxide whereas daizein had no protective effect. In the same cell line, both 
genistein and daidzein significantly increased γ-glutamylcysteine-synthetase levels and were 
able to induce increases in cytosolic accumulation and nuclear translocation of Nrf2. In 
contrast GSH levels increased only in the cells treated with daidzein; whereas with genistein, 
they were significantly lower, due to its sequestration by metabolism. In addition, cytosolic 
levels of Nrf1, and the degree to which Nrf1 underwent nuclear translocation, were significantly 
higher in cells exposed to genistein than in those exposed to daidzein. Therefore it appeared 
that protection by genistein depended on its induction of GPx and changes in Nrf1 activation, 
suggesting that they may underlie its protective effects in endothelial cells, and be mediated 
by intracellular metabolism to THIF that is only relevant to genistein but not daidzein were 
hydroxylation cannot occur. Future work would be needed to fully investigate these metabolic 
difference in view of a more complete understanding on their molecular mechanism of action, 















































































































Figure 1. Chemical structure of genistein and genistin.  
Figure 2. Genistein metabolic transformations. The glycoside genistin is not absorbed 
intact but hydrolized in the stomach and in the colon. Genistein can be absorbed by passive 
diffusion in the small intestine or undergo further biotransformation to a range of metabolites, 
such as dihydrogenistein  and 6’-hydroxy-O demethylangolensin (DMA) formed in the colon. 
Genistein can also undergo metabolic conjugation to glucuronic acid or sulphuric acid in the 
intestinal epithelium and in the liver. Intracellularly, genistein is hydroxylated to 5,7,3’,4’-
tetrahydroxyisoflavone (THIF; orobol) and two glutathionyl conjugates of THIF can also be 
formed. 
Figure 3. Genistein and THIF: intracellular mechanism of action. Genistein enters cells 
where it is subject the CYP450-induced intracellular metabolism yielding THIF.  THIF may also 
react with intracellular GSH to form the adduct THIF-GSH, inducing a reduction of intracellular 
GSH and an increased DNA damage. Genistein and THIF might induce the transcription of 
antioxidant enzymes: more specifically genistein directly activate the translocation of Nrf2, 
which will increase the transcription of γ-GCS, leading to increases in GSH synthesis, whereas 
THIF stimulates the release of Nrf1 with the subsequent translocation into the nucleus where 
it may interact with the electrophile response element and induce the transcription of GPx. 
THIF triggers the activation of the MAP kinase p38. Active p38 prevents the phosphorylation 
of cyclin B1 and hence its transport to the nucleus, an event essential for correct functioning 
of the cdc2-cyclin B1 complex.  In addition, active p38 may undergo translocation to the 
nucleus where it directly inhibits the phosphorylation/activation of cdc2, thereby blocking entry 
of cells into mitosis (G2-M block). 
THIF formation also induces the activation of ATR, accompanied by the phosphorylation of 
both p53 and Chk1, downstream signals playing an important role in DNA damage checkpoint 
control. One of p53 downstream targets is the tumour suppressor protein p21 Waf1/Cip1, 
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which can act as an inhibitor of cell cycle progression via its ability to inhibit cdc2. THIF-
induced activation of Chk1 is paralleled by an inactivation of cdc25C phosphatase, causing it 




• The isoflavone genistein is present in soy products, mainly in the form of glycosides 
such as genistin. 
• Genistein consumption is associated to numerous potential health benefits, such as 
estrogenic activity, anticancer effects, antioxidant actions, anti-inflammatory activity and 
cardiovascular effects. 
• The biological effects of genistein in cells and tissues will be dependent on its 
absorption, metabolism and distribution. 
• The most prevalent forms in the diet do not necessarily give rise to the highest 
concentrations in vivo and metabolites may be present in relevant amounts. 
• Glycosilated forms of genistein are not absorbed intact in humans and their 
bioavailability requires hydrolysis to occur in the stomach and/or large intestine. 
• Genistein can be absorbed by passive diffusion in the small intestine, or can be 
converted to dihydrogenistein  and 6’-hydroxy-O demethylangolensin (DMA) in the colon. 
• Genistein can undergo phase II metabolic conjugation to glucuronic acid or sulphuric 
acid, catalyzed by UDP-glucuronyl transferase or sulfotransferase enzymes in the intestinal 
epithelium and in the liver. 
• Intracellularly, genistein is subjected to metabolic transformation by CYP450 enzymes 
leading to the formation of both 5,7,3’,4’-tetrahydroxyisoflavone (THIF; orobol) and two 
glutathionyl conjugates of THIF. 
• THIF formation is crucial for cellular activity, acts via a mechanism involving oxidative 
DNA oxidation and the activation of downstream signaling pathways, and may mediate the 
effects of genistein intracellularly. 
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Key facts of flavonoids metabolism 
• The biological properties of flavonoids in the diet and their activity in vivo are 
dependent on the extent of their biotransformation and conjugation during absorption.  
• The most prevalent flavonoids in the diet do not necessarily correspond to the most 
bioactive forms in vivo. 
• Glycosylation has a great influence on flavonoid absorption and glycosilated forms 
may not be absorbed intact in humans.  
• Dietary flavonoids are subjected to extensive phase I (oxidation, reduction, hydrolysis) 
and phase II (conjugation to glucuronic acid, sulfate, glutathione) metabolic reactions catalized 
by enzymes such as cytochrome P450 found both in the small intestine and the liver. 
• Further transformations of flavonoids may occur in the colon, where bacterial enzymes 
may catalyse many reactions including hydrolysis, dehydroxylation, demethylation, ring 
cleavage and decarboxylation as well as rapid de-conjugation, and are also able to catalyse 
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